Aricept Fact Sheet
Esai and Pfizer; patent expires 2010.
Mild to moderate Alzheimer’s dementia.
- Moderate to severe Alzheimer's dementia.
- Off-label use for mild cognitive impairment.
Acetylcholinesterase inhibitor. Enhances brain cholinergic function.
- 5 mg white and 10 mg yellow tablets
- Orally disintegrating tablets: 5 mg white and 10 mg yellow.
- Start at 5 mg QD, increase to 10 mg QD after four weeks. Morning dosing may minimize insomnia and vivid dreams.
- No dose adjustment needed in renal impairment; only a minimal dose decrease required in hepatic impairment.
Most common: nausea, diarrhea, insomnia, fatigue.
- Occasionally: agitation, vivid dreams.
- May aggravate stomach ulcers (potential class effect of all cholinesterase inhibitors)
- Pregnancy risk category C.
Partly metabolized by P450 3A4, so theoretically levels could be increased by 3A4 inhibitors such as Luvox, and levels could be decreased by inducers such as Tegretol.
Metabolized mostly by liver; about 20% is excreted unchanged in the urine.
- Half-life 3 days.
Aricept has the best evidence for effectiveness in mild cognitive impairment of all cholinesterase inhibitors.
Earn CME Credit Instantly!
Not quite ready for a one-year subscription to The Carlat Psychiatry Report? Need CME credits on a particular topic or on a tight deadline?
Try our A la Carte CME! You can buy single or multiple credits of continuing education, without committing to a year-long newsletter subscription.
Already an A la Carte subscriber? Click here to go to your a la carte page
Steve Balt Interviewed by NPR
Our own Steve Balt was interviewed on NPR's "Talk of the Nation" on psychiatry's shift toward drugs and away from talk therapy.
After 10 years at the helm of TCPR, Dr. Carlat has handed over editor-in-chief duties to Dr. Steve Balt. We’re excited to welcome him aboard! Read More...